- Home
- KROS vs AVK Comparison
KROS vs AVK Comparison
Compare KROS & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- AVK
- Stock Information
- Founded
- KROS 2015
- AVK 2003
- Country
- KROS United States
- AVK United States
- Employees
- KROS N/A
- AVK N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- AVK Trusts Except Educational Religious and Charitable
- Sector
- KROS Health Care
- AVK Finance
- Exchange
- KROS Nasdaq
- AVK Nasdaq
- Market Cap
- KROS 461.6M
- AVK 411.0M
- IPO Year
- KROS 2020
- AVK N/A
- Fundamental
- Price
- KROS $11.47
- AVK $11.45
- Analyst Decision
- KROS Buy
- AVK
- Analyst Count
- KROS 11
- AVK 0
- Target Price
- KROS $30.00
- AVK N/A
- AVG Volume (30 Days)
- KROS 953.9K
- AVK 112.9K
- Earning Date
- KROS 05-07-2025
- AVK 01-01-0001
- Dividend Yield
- KROS N/A
- AVK 11.85%
- EPS Growth
- KROS N/A
- AVK N/A
- EPS
- KROS N/A
- AVK N/A
- Revenue
- KROS $3,550,000.00
- AVK N/A
- Revenue This Year
- KROS $16.65
- AVK N/A
- Revenue Next Year
- KROS $107.46
- AVK N/A
- P/E Ratio
- KROS N/A
- AVK N/A
- Revenue Growth
- KROS 2250.99
- AVK N/A
- 52 Week Low
- KROS $9.78
- AVK $9.24
- 52 Week High
- KROS $72.37
- AVK $12.16
- Technical
- Relative Strength Index (RSI)
- KROS 44.86
- AVK 26.63
- Support Level
- KROS $10.62
- AVK $11.42
- Resistance Level
- KROS $12.28
- AVK $11.98
- Average True Range (ATR)
- KROS 0.60
- AVK 0.18
- MACD
- KROS 0.34
- AVK -0.06
- Stochastic Oscillator
- KROS 51.20
- AVK 4.29
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.